|
Controversial Super Bowl Ad Sparks Debate Over Compounded GLP-1 Medications
|
Written by: J. Smith |
Hits: 779
|
|
Novo Nordisk's CagriSema Gains Momentum Amid Investor Optimism and Legal Scrutiny
|
Written by: J. Smith |
Hits: 916
|
|
FDA Approves Ozempic for Chronic Kidney Disease in Type 2 Diabetes
|
Written by: J. Smith |
Hits: 743
|
|
Novo Nordisk's Amycretin Shows 22% Weight Loss in Early Trial Results
|
Written by: J. Smith |
Hits: 886
|
|
Novo Nordisk and Valo Health Expand AI-Powered Partnership to Address Cardiometabolic Diseases
|
Written by: J. Smith |
Hits: 600
|
|
Semaglutide 7.2 mg Demonstrates Greater Weight Loss but Faces Market Challenges
|
Written by: J. Smith |
Hits: 607
|
|
2025 Outlook: GLP-1 Supply Gains Momentum Amid Expansion Efforts
|
Written by: J. Smith |
Hits: 4774
|
|
Abbott and Dexcom Settle Global Patent Disputes Over CGM Technologies
|
Written by: J. Smith |
Hits: 1049
|
|
Novo Nordisk’s CagriSema Falls Short of Investor Expectations Despite Promising Weight-Loss Results
|
Written by: J. Smith |
Hits: 677
|
|
FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity
|
Written by: J. Smith |
Hits: 770
|
